Reticulocyte dynamic and hemoglobin variability in hemodialysis patients treated with Darbepoetin alfa and C.E.R.A.: a randomized controlled trial. by Forni, V. et al.
Forni et al. BMC Nephrology 2013, 14:157
http://www.biomedcentral.com/1471-2369/14/157RESEARCH ARTICLE Open AccessReticulocyte dynamic and hemoglobin variability
in hemodialysis patients treated with Darbepoetin
alfa and C.E.R.A.: a randomized controlled trial
Valentina Forni1,2, Giorgia Bianchi1, Adam Ogna1, Igor Salvadé1, Philippe Vuistiner3, Michel Burnier2
and Luca Gabutti1*Abstract
Background: In a simulation based on a pharmacokinetic model we demonstrated that increasing the
erythropoiesis stimulating agents (ESAs) half-life or shortening their administration interval decreases hemoglobin
variability. The benefit of reducing the administration interval was however lessened by the variability induced by
more frequent dosage adjustments. The purpose of this study was to analyze the reticulocyte and hemoglobin
kinetics and variability under different ESAs and administration intervals in a collective of chronic hemodialysis
patients.
Methods: The study was designed as an open-label, randomized, four-period cross-over investigation, including 30
patients under chronic hemodialysis at the regional hospital of Locarno (Switzerland) in February 2010 and lasting
2 years. Four subcutaneous treatment strategies (C.E.R.A. every 4 weeks Q4W and every 2 weeks Q2W, Darbepoetin
alfa Q4W and Q2W) were compared with each other. The mean square successive difference of hemoglobin,
reticulocyte count and ESAs dose was used to quantify variability. We distinguished a short- and a long-term
variability based respectively on the weekly and monthly successive difference.
Results: No difference was found in the mean values of biological parameters (hemoglobin, reticulocytes, and
ferritin) between the 4 strategies. ESAs type did not affect hemoglobin and reticulocyte variability, but C.E.R.A
induced a more sustained reticulocytes response over time and increased the risk of hemoglobin overshooting
(OR 2.7, p = 0.01). Shortening the administration interval lessened the amplitude of reticulocyte count fluctuations
but resulted in more frequent ESAs dose adjustments and in amplified reticulocyte and hemoglobin variability.
Q2W administration interval was however more favorable in terms of ESAs dose, allowing a 38% C.E.R.A. dose
reduction, and no increase of Darbepoetin alfa.
Conclusions: The reticulocyte dynamic was a more sensitive marker of time instability of the hemoglobin response
under ESAs therapy. The ESAs administration interval had a greater impact on hemoglobin variability than the ESAs
type. The more protracted reticulocyte response induced by C.E.R.A. could explain both, the observed higher risk of
overshoot and the significant increase in efficacy when shortening its administration interval.
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The implementation of erythropoiesis stimulating agents
(ESAs) in clinical practice has been one of the most im-
portant innovations in the management of anemia in
chronic hemodialysis (HD) patients. The ESAs therapy
implicates however a non-physiologic stimulation of the
erythropoietic process and has been identified as one of
the most influential causative factors of hemoglobin
variability in HD patients.
Instability over time of the hemoglobin values is a
physiological biological event, but is accentuated in HD
patients under synthetic drug stimulation of the erythro-
poiesis [1]. In fact, ESAs therapy induces intermittent
peaks of plasmatic erythropoietin (EPO), as compared
with the more stable concentration profile of endogen-
ous EPO under the close feed-back loop between
erythropoietin concentration and EPO-sensing and pro-
ducing system acting in physiologic circumstances [1].
Several other aspects of the ESAs therapy may contrib-
ute to destabilize the hemoglobin profile over time, such
as drug-related factors (pharmacokinetic and bioavail-
ability) and the dose adjustment strategy (doses, dosage
frequency) applied by the prescriber [2-5].
The most recent history of ESAs has been signed by
the development of long-acting compounds with distinct
molecular structure compared with the original epoetin
alfa and beta, such as Darbepoetin alfa (half-life 48.8 ±
5.2 hours after subcutaneous (s.c) administration) [6,7]
and C.E.R.A. (Continuous erythropoietin receptor activa-
tor) (139 ± 20 hours after s.c administration) [8,9],
resulting in the recommendation to clinicians to lengthen
the administration interval, up to once monthly.
In the absence of evidence about the impact of the half-
life and administration interval of ESAs on hemoglobin
variability, we first performed a simulation based on a
pharmacokinetic model. The task for the nephrologists
participating in the study was to achieve and maintain, on
a Visual Basic Excel table, the hemoglobin target using 3
different ESAs, with a half-life of 24, 48 and 138 hours,Figure 1 Study design. Schema representing the four-period cross-over in
scheduled at 4 weeks intervals (Q4W) and 2 periods with ESAs administratiadministered weekly or monthly. This study allowed us to
demonstrate: (i) the hemoglobin variability decreases with
an increase of the ESAs half-life and with a shortening
of the administration interval; (ii) the monthly prescrip-
tion compared to the weekly one is associated with less
dosage adjustments, (iii) the number of ESAs posology
modifications correlate directly with hemoglobin vari-
ability [4].
Aware of the limits of the simulation tool, aiming at
verifying our results in the clinical setting and in order to
analyze the cellular kinetics of erythopoiesis under differ-
ent therapeutic strategies, we studied the relationship
between two relevant pharmacodynamic response param-
eters, hemoglobin and reticulocytes, under different ESAs
(C.E.R.A and Darbepoetin alfa) and administration inter-
vals (every 2 weeks, Q2W; every 4 weeks, Q4W) in a col-
lective of chronic HD patients.
Methods
The study was designed as an open-label, randomized,
four-period cross-over investigation (Figure 1), consider-
ing for inclusion all patients under hemodialysis at the
regional hospital of Locarno (Switzerland) in February
2010.
We enrolled 31 chronic patients aged 18 years or
older, undergoing dialysis 3 times a week for at least
8 weeks before screening, necessitating continuous sub-
cutaneous treatment with weekly Darbepoetin alfa or
Erythropoietin beta to maintain hemoglobin (Hb) tar-
gets. Exclusion criteria were pregnancy or not respecting
the above mentioned conditions. The patients were ran-
domly assigned to subcutaneous C.E.R.A or Darbepoetin
alfa, independent of previous ESAs therapy. Patients
randomization was conducted by computerized proced-
ure by a co-investigator; the randomization was balanced
by groups of six. The randomization codes were com-
municated to the co-investigators implicated in ESAs pre-
scription and to the dialysis nurses responsible of drug
administration. Taking into account the administration ofvestigation, composed of 2 periods with ESAs administration
on scheduled at 2 weeks intervals (Q2W).
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toring compliance was indicated.
Study drug was switched over at the beginning of each
treatment period. Each period lasted 6 months; the first
month of each period was not considered in the analysis
(wash-in phase).
The starting dose of ESA was based on patient’s cumu-
lated dose in the month before randomization according
to approved labeling [10].
During the study, doses were adjusted to maintain Hb
values within a range of 11.0-13.0 g/dl. Dose adjust-
ments were scheduled at 4 weeks intervals (Q4W) dur-
ing the first two periods (P1-2) and every 2 weeks
(Q2W) during periods three and four (P3-4). P1-2 and
P3-4 were intercalated by a 2-month transition phase,
during which the drug study was switched but continued
to be administrated at Q4W interval (to discriminate be-
tween the effect of study drug switch and administration
interval change). A protocol directed ESA dose adjust-
ment according to approved labeling [11], based on the
most current Hb value measured 1 week previous to the
planned administration.
In the Hb target 11.0-13.0 g/dl, dose was continued
unchanged. If the rise in Hb was greater than 2 g/dl in
four weeks, dose was reduced by 25%. If the Hb
exceeded 13.0 g/dl, dose was temporarily withheld
until the Hb decreased under 12 g/dl, at which point
therapy was reinitiated at 50% lower than the previous
dose.
If the increase in Hb was inadequate (less than 1 g/dl),
the dose was further increased by 25%.
When switching from Q4W to Q2W administration
interval, the monthly ESA total dose was maintained un-
changed (conversion factor 1:1), but divided in two ad-
ministrations. Body weight was not integrated in the
ESA dose adjustment protocol.
Of note, Darbepoetin alfa is licensed in Switzerland for
one-monthly administration, in contrast to the many
other European countries (TIW, Q1W, Q2W).
Supplementary iron carboxymaltose was administered
if necessary to stabilize serum ferritin between 100 and
500 μg/l.
Patients were assessed Q1W with hemoglobin values
(Hb) and reticulocyte counts (ret), while serum ferritin
was measured Q4W.
Hemoglobin variability was the primary outcome while
reticulocyte variability, induced reticulocyte response,
risk of hemoglobin overshooting and ESAs efficacy com-
paring 4 to 2 week administration interval were the sec-
ondary ones.
The results of the months following a red blood cells
transfusion or an overt bleeding episode were not con-
sidered in the analysis. Data obtained during patient
hospitalization for any reason were similarly suppressed.The protocol of the study was approved by the local
Ethical Committee (Comitato Etico Cantonale della
Repubblica e Cantone Ticino). All the patients gave writ-
ten informed consent prior to enrolling in the study.Statistical analysis
To assess the time-variability of both hemoglobin and
reticulocytes in Q4W, data were grouped over a four-
week period corresponding to the number of weeks fol-
lowing each EPO injection. Linear mixed-effect models
were applied on these data with individual random ef-
fects. A parabolic function appeared to best fit the data.
Adjustments for age and sex as well as for the dose of
EPO and iron were made. Reticulocytes were log-
transformed to better approach normality. For Q2W, the
time between two consecutive injections was too short
to allow similar analyses to be performed.
In absence of previous literature permitting an estima-
tion of an expected between-groups difference, no sam-
ple size calculation had been driven. Moreover all
patients who agreed to participate had been included in
the study, so the sample size was the largest we could
provide.
The mean square successive difference (MSSD) was
used to quantify temporal instability in terms of both
variability and temporal dependency over time. The
MSSD is the average of the squared difference between
successive observations [12]. We distinguished a short-
term variability (ST-MSSD) based on the weekly succes-
sive difference, from a long-term variability (LT-MSSD)
founded on the monthly successive difference.
Both ST-MSSD and LT-MSSD were assessed for
hemoglobin, reticulocytes and ESA (only LT-MSSD).
Linear mixed-effect models predicting the effect of
ESAs type on the variability (ST-MSSD and LT-MSSD)
of hemoglobin were developed, and adjusted for ESAs
administration order and ESAs administration interval.
As ST-MSSD and LT-MDDS were right-skewed vari-
ables, log-transformed values were used in the analyses
to better approach normality.
Statistical analyses were performed using R (version
2.12.0) with the “lme” function from the “nlme” package
[13]. Significance level was P < 0.05.Results
Study population
A total of 31 patients were enrolled in the trial and ran-
domized into 2 treatment groups (16 to C.E.R.A and 15
patients to Darbepoetin alfa) at Q4W administration
interval. Of these, 30 patients received at least one dose
of the study drug, while 1 patient randomized to C.E.R.A
died before the first study drug was administrated.
Table 2 Blood parameter, treatment dose and variability
(MSSD) of Period 1–2 (Q4W ESAs administration interval)
C.E.R.A Darbepoetin alfa p-value
(n = 30) (n = 30)
Hemoglobin, g/dl
(mean, SD)
11.3 (0.2) 11.2 (0.2) 0.65
Reticulocyte count,
cells/μl (mean, SD)
69891 (18153) 67047 (18038) 0.55
Ferritin, μg/l
(mean, SD)
438.7 (190.8) 429.9 (142.7) 0.84
Cumulated ESA
dose, μg (mean, SD)
788.1 (554.6) 867.9 (721.4) 0.65
Cumulated iron
dose, μg (mean, SD)
703.7 (325) 781.5 (306.4) 0.37
ST-MSSD Hb,
g2/dl2 (mean, SD)
0.57 (0.58) 0.52 (0.38) 0.73
LT-MSSD Hb,
g2/dl2 (mean, SD)
0.62 (0.47) 0.32 (0.36) 0.009
ST-MSSD Ret,
cells2/μl2
(mean, SD)
26.9x108 (28.2x108) 37.8x108 (36.1x108) 0.20
LT-MSSD-Ret,
cells2/μl2 (mean, SD)
4.8x108 (5.7x108) 2.5x108 (4.6x108) 0.14
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assessment because of death (2 in the C.E.R.A., 32 weeks
of follow-up lost in P1-2; 2 in the Darbepoetin alfa
group, 23 weeks of follow-up lost in P1-2) or renal
transplantation (2 in the Darbepoetin alfa group,
16 weeks of follow-up lost in P1-2).
Out of the 24 patients who completed P1-2, 5 pa-
tients could not be included in P3-4, because of too low
EPO dose, not allowing to be split in 2 half-doses. Dur-
ing P3-4, out of 19 patients (11 of the C.E.R.A and 8 of
the Darbepoetin alfa group), 4 patients prematurely
interrupted the assessment because of death (1 in the
Darbepoetin alfa group, 14 weeks of follow-up lost) or
transfer to other hemodialysis centers (2 in the C.E.R.A,
24 weeks of follow-up lost; 1 in the Darbepoetin alfa
group, 16 weeks of follow-up lost).
Patient demographic data, clinical characteristics and
laboratory results at baseline are presented in Table 1.
The most frequent etiologies of chronic kidney disease
(CKD) were hypertension (29%), miscellaneous (diabetes
and hypertension) (25.8%), diabetes (6.5%), glomerulo-
nephritis (9.7%), interstitial nephritis/pyelonephritis (6.4%)
or other/unknown causes (22.6%).
Efficacy
Data concerning hemoglobin, reticulocyte count, ferritin,
cumulated ESAs and iron dose are presented in Table 2
(P1-2, Q4W) and Table 3 (P3-4, Q2W); data comparing
P1-2 and P3-4, restricted to the 19 patients whoTable 1 Baseline characteristics of the study participant
according to ESAs randomization group during P1
C.E.R.A Darbepoetin
alfa
p-value
(n = 15) (n = 15)
Sex (male), N (%) 8 (53.3%) 9 (60%) 0.71
Age, year (mean, SD) 70.5 (9.7) 69.3 (10.3) 0.73
Dry weight, kg (mean, SD) 66.8 (18.5) 77.0 (16.1) 0.12
Diabetic, % 53 47 0.71
Hypertensive, % 93 93 1.0
Dialysis duration,
hours/week (mean, SD)
11.5 (1) 11.1 (1) 0.34
Time on dialysis, years
(mean, SD)
3.1 (2.9) 2.5 (1.9) 0.46
Hemoglobin, g/dl
(mean, SD)
10.9 (1.3) 11.3 (1.1) 0.37
Reticulocyte count, cells/μl
(mean, SD)
34147 (12823) 38711 (20368) 0.47
Ferritin, μg/l (mean, SD) 357.4 (213.5) 361.8 (127.3) 0.95
Iron dose, mg/month
(mean, SD)
173.3 (103.3) 186.7 (51.6) 0.66
ESA dose, μg/month
(median, IQR)
120 (75–158) 100 (64–146) 0.32
SD Standard deviation, IQR Inter-quartile range.participated in the 2 study phases, are summarized in
Table 4. Tables 2, 3, 4, 5 show the combined results of
the 2 randomization groups.
Overall, data of 572 patient-weeks under Darbepoetin
alfa and 571 patient-weeks under C.E.R.A in P1-2, re-
spectively 353 patient-weeks under Darbepoetin alfa and
359 patient-weeks under C.E.R.A in P3-4, were analyzed.Table 3 Blood parameter, treatment dose and variability
(MSSD) of Period 3–4 (Q2W ESAs administration interval)
C.E.R.A Darbepoetin alfa p-value
(n = 19) (n = 19)
Hemoglobin, g/dl
(mean, SD)
11.6 (0.6) 11.4 (0.6) 0.24
Reticulocyte count,
cells/μl (mean, SD)
78915 (20625) 72765 (18220) 0.34
Ferritin, μg/l
(mean, SD)
433.2 (105.3) 478.9 (98.3) 0.18
Cumulated ESA
dose, μg (mean, SD)
895 (657.7) 865.6 (622.9) 0.89
Cumulated iron
dose, μg (mean, SD)
712.5 (272.9) 611.1 (286.7) 0.30
ST-MSSD Hb,
g2/dl2 (mean, SD)
0.52 (0.40) 0.67 (0.45) 0.28
LT-MSSD Hb,
g2/dl2 (mean, SD)
1.25 (1.10) 1.01 (1.24) 0.54
ST-MSSD Ret,
cells2/μl2 (mean, SD)
16.5x108 (14.4x108) 20.3x108 (20.5x108) 0.52
LT-MSSD-Ret ,
cells2/μl2 (mean, SD)
12.1x108 (15.5x108) 6.9x108 (9.7 x108) 0.24
Table 4 Blood parameter, treatment dose and variability
(MSSD) of Period 1–2 vs. Period 3–4, C.E.R.A
C.E.R.A. Period 1–2 Period 3–4 p-value
(n = 19) (n = 19)
Hemoglobin, g/dl
(mean, SD)
11.2 (1.2) 11.6 (0.7) 0.16
Reticulocyte count,
cells/μl (mean, SD)
68367 (17794) 78916 (20626) 0.10
Ferritin, μg/l
(mean, SD)
444.4 (140.9) 433.1 (105.3) 0.78
Cumulated ESA
dose, μg (mean, SD)
950.3 (544.5) 895 (657.7) 0.79
Cumulated iron
dose, μg (mean, SD)
684.2 (285.3) 712.5 (272.9) 0.77
ST-MSSD Hb, g2/dl2
(mean, SD)
0.56 (0.67) 0.52 (0.40) 0.83
LT-MSSD Hb, g2/dl2
(mean, SD)
0.64 (0.51) 1.25 (1.10) 0.03
ST-MSSD Ret,
cells2/μl2 (mean, SD)
35.8x108 (29.6x108) 16.5x108 (14.4x108) 0.01
LT-MSSD Ret,
cells2/μl2 (mean, SD)
5.4x108 (7.3x108) 12.1x108 (15.5x108) 0.10
LT-MSSD ESA, μg2
(mean, SD)
10609 (16963) 29043 (12641) 0.25
Table 5 Blood parameter, treatment dose and variability
(MSSD) of Period 1–2 vs. Period 3–4, Darbepoetin alfa
Darbepoetin alfa Period 1–2 Period 3–4 p-value
(n = 19) (n = 19)
Hemoglobin, g/dl
(mean, SD)
11.0 (0.9) 11.4 (0.7) 0.15
Reticulocyte count,
cells/μl (mean, SD)
67543 (19668) 72766 (18220) 0.41
Ferritin, μg/l
(mean, SD)
465.9 (156.1) 478.9 (98.3) 0.76
Cumulated ESA
dose, μg (mean, SD)
1121.6 (744.6) 865.6 (622.9) 0.26
Cumulated iron
dose, μg (mean, SD)
705.6 (340.4) 611.1 (286.7) 0.37
ST-MSSD Hb,
g2/dl2 (mean, SD)
0.54 (0.35) 0.67 (0.45) 0.30
LT-MSSD Hb,
g2/dl2 (mean, SD)
0.28 (0.24) 1.01 (1.24) 0.02
ST-MSSD Ret,
cells2/μl2 (mean, SD)
48.4x108 (40.3x108) 20.3x108 (20.5x108) 0.01
LT-MSSD Ret,
cells2/μl2 (mean, SD)
2.0x108 (2.4x108) 6.9x108 (9.7 x108) 0.04
LT-MSSD ESA, μg2
(mean, SD)
1701 (2113) 15650 (41055) 0.07
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hemoglobin response to subcutaneous ESA was charac-
terized by an oscillatory movement over 1 month,
reaching the maximal level about 2½ weeks after injec-
tion. There were no significant interactions between
ESAs type and time (p = 0.7) nor time2 (p = 0.8),
suggesting any significant time course difference of
hemoglobin response between ESAs. The hemoglobin
level was slightly higher in participants under C.E.R.A
than in those under Darbepoetin alfa, but the difference
was not significant (p = 0.2). Similarly, the reticulocyte
response followed an oscillatory cyclic movement over
1 month with both ESAs. The monthly oscillatory time
course differed between C.E.R.A and Darbepoetin alfa
(the interaction terms were clearly significant: p < 0.001
for time and p < 0.001 for time2). In participants under
Darbepoetin alfa, the reticulocyte level reached its max-
imum within the first days after injection but it then de-
creased almost linearly, whereas under C.E.R.A, the
maximum level was slightly lower, but it remained nearly
constant up to two weeks after the injection (secondary
outcome). We found a significant correlation between
hemoglobin and reticulocyte count (p < 0.001) after
adjusting for time, ESAs type, baseline Hb, ESAs-dose
and cumulated dose, iron dose and cumulated iron.
With Q2W ESAs administration (P3-4) (Figure 3),
the hemoglobin time course became more irregular. We
observed, indeed, a loss of the systemic monthly cyclic
behavior, characterizing P1-2.The reticulocyte response preserved a cyclic oscillatory
course over 1 month. Unlike the monophasic movement
observed in P1-2, the oscillation became biphasic in P3-
4, reaching its peak within the first week after ESAs in-
jection and returning to the baseline within 2 weeks.
Data concerning short-term (week-to-week) variability
(ST-MSSD) and long-term (month-to-month) variability
(LT-MSSD) are summarized in Tables 2, 3, 4, 5.
For hemoglobin, no significant difference was found in
ST-MSSD, when modifying ESAs or administration
interval. However, a significant hemoglobin LT-MSSD
increase was found when shortening the administration
interval from Q4W to Q2W, both for C.E.R.A (p = 0.03)
and Darbepoetin alfa (p = 0.02) (primary outcome). Re-
ticulocyte LT-MSSD was found to predict hemoglobin
LT-MSSD (p < 0.0001), after adjusting for ESA type, ad-
ministration order and interval.
Reticulocyte LT-MSSD increased when shortening the
administration interval with both ESAs. The difference was
significant in the Darbepoetin alfa group (p = 0.04), but
didn’t reach significance in the C.E.R.A. group (p = 0.1).
Reticulocyte ST-MSSD decreased significantly when
shortening the administration interval from Q4W to
Q2W, both for C.E.R.A (p = 0.01) and Darbepoetin alpha
(p = 0.01).
Concerning ESAs, when analyzing the start and final
dose utilized in both study phases, we observed that:
Darbepoetin alfa monthly dose significantly increased
from mean (sd) 180 (145) to 266 (172) μg over P1-2
Figure 2 Hemoglobin and reticulocyte time course, Q4W administration interval. Hb, ret and ESA dose as a function of time at 4 weeks
ESAs-administration interval; C.E.R.A. black dash line, Darbepoietin alfa black solid line. Vertical lines correspond to ESA administration.
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mean (sd) 202 (185) to 170 (168) μg (p = 0.3) (Figure 4);
C.E.R.A monthly dose was unchanged over P1-2, from
mean (sd) 161 (106) to 202 (167) μg (p = 0.3) , but signifi-
cantly decreased over period P3-4, from 244 (222) to 151
(154) μg (p = 0.01) (Figure 5) (secondary outcome). After
adjustment for confounding factors (ESAs administration
interval, cumulated ESAs dose prior to the event, cumu-
lated iron dose), the risk of Hb overshooting (defined as
Hb > 12.0 g/dl) was found to be predicted from ESA type,
with a higher risk for C.E.R.A. (OR 2.7, p = 0.01) (second-
ary outcome). ESAs type and administration interval were
not found to predict Hb values < 10 g/dl, which were cor-
related with cumulated ESA dose (p = 0.02).
9 patients necessitated red blood cells transfusion dur-
ing the study, in 2 cases for overt bleeding, in 6 cases
after a surgical intervention and the remaining in the
course of an infectious disease. Because of transfusion,
data of 36 weeks were not considered in analyses. 33
hospitalizations occurred during the study, generating a
loss of 52 weeks of follow-up.Discussion
The current study was designed to examine the influ-
ence of two long half-life erythropoiesis stimulating
agents (ESAs) administered subcutaneously at different
intervals on the cellular kinetics of erythropoiesis under
conditions of standard clinical practice in hemodialysis
patients and to verify the findings of a simulation based
on a pharmacokinetic model suggesting a correlation be-
tween hemoglobin variability and both half-life and ad-
ministration interval [4].
Hemoglobin in dialysis patients is an instable param-
eter, influenced by several measure-related (analysis
bias), patients-related (hydration [14], inflammation
[15,16], nutrition [17,18], blood loss, hospitalization [5])
and treatment-related factors (dialysis adequacy [19], ad-
ministration of intravenous iron, correction of iron defi-
ciency and ESAs therapy [5]).
Data comparing the influence of different ESAs on
hemoglobin variability are scarce and contrasting
[5,20-22]. The primordial challenge in this research field
is how to define and assess correctly “variability”. Several
Figure 3 Hemoglobin and reticulocyte time course, Q2W administration interval. Hb, ret and ESA dose as a function of time at 4 weeks
ESAs-administration interval; C.E.R.A. black dash line, Darbepoietin alfa black solid line. Vertical lines correspond to ESA administration.
Figure 4 Start- and end- monthly ESA dose, Darbepoetin alfa. Starting and end-monthly dose of Darbepoietin alfa at 4 weeks (Q4W) and
2 weeks (Q2W ) administration intervals. Boxes represent 25th and 75th percentiles, whiskers 5th and 95th percentiles. N = 19.
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Figure 5 Start- and end- monthly ESA dose, C.E.R.A. Starting and end-monthly dose of C.E.R.A at 4 weeks (Q4W) and 2 weeks (Q2W)
administration intervals. Boxes represent 25th and 75th percentiles, whiskers 5th and 95th percentiles. N = 19.
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deviation, autocorrelation …) have been used and several
definitions have been formulated. The most common
one is to define a non-physiological “cycle”, an “oscilla-
tion of Hb >1.5 g/dL over >8 weeks, during which Hb
levels increased or decreased and then reverse to the ini-
tial trajectory” [5]. The limits of most of these indices
and definitions, are that they do not consider that
hemoglobin acts as a non-stationary time series, in
which a systematic increase or decrease in overall level
of response occurs over time (temporal dependency).
Unlike the standard deviation and the autocorrelation,
measures based on successive change allow quantifying
temporal instability in terms of both variability and tem-
poral dependency over time. An example is the mean
square successive differences (MSSD), which implies the
average of the squared difference between successive
observations. Further, the MSSD allows to distinct short-
term (e.g. week-to-week) from long-term instability, pro-
ducing fluctuations across a long-term duration (e.g.
month-to-month). MSSD could be a more precise esti-
mator of hemoglobin instability over time.
A second important limit of the studies about
hemoglobin variability under ESAs is that they ignore
the effect of ESAs on cellular production, namely the
ESAs induced reticulocyte response. If and how reticulo-
cytes are implicated in the phenomenon of hemoglobin
variability is actually not known.
With the current four-period cross-over study, we ana-
lyzed the influence of 2 ESAs (C.E.R.A. and Darbepoietin
alfa) and 2 administration intervals (Q4W, Q2W) on
hemoglobin and reticulocyte response. Therefore, 4 treat-
ment strategies (C.E.R.A./Q4W, C.E.R.A./Q2W, Darbepoetinalfa/Q4W, Darbepoetin alfa/Q2W) were compared with
each other.
No difference was found in the mean values of bio-
logical parameters (hemoglobin, reticulocytes, and ferritin)
between the 4 strategies. However, Q2W administration
interval seemed to be more favorable in terms of ESAs
dose, allowing over the 6 observation months a 38%
C.E.R.A. dose reduction, and no increase of Darbepoetin
alfa (secondary outcome). This finding about C.E.R.A. is
concordant with previous observations [23]. Retrospect-
ively, we can suggest that the hemoglobin overshooting
observed under C.E.R.A in the Q2W administration inter-
val is probably due to an inadequate conversion factor
(1:1) of ESAs dose in the transition from Q4W to Q2W
administration interval (however, this was the conversion
factor suggested by previous literature recommendations
[9]) and to a too generous ESAs adjustment protocol in
the maintenance phase (however approved by current
labeling when the study was designed [11]).
The great sensibility of reticulocyte dynamic to ESAs
therapy was evidenced by several factors, namely the evi-
dent oscillatory response induced by the ESAs pulse, the
contracted short-term (week-to-week) variability when
shortening the administration interval and splitting the
ESAs dose, the amplified long-term (month-to-month)
time instability under 2 week administration interval.
Accordingly to its extended half-life, C.E.R.A. induced a
more sustained erythropoietic response, as evidenced by
the more protracted reticulocyte production under
monthly administration intervals (secondary outcome).
This can also explain the increased risk of hemoglobin
overshooting (Hb > 12.0 g/dl) observed under C.E.R.A
(secondary outcome).
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namic seemed to be less sensitive to ESAs therapy strat-
egy. No significant difference was found in the oscillatory
course using the two different ESAs. The administration
interval impacted on the monthly Hb course (loss of the
cyclic oscillatory movement under Q2W administration),
without modifying short-term week-to-week variability.
The long-term (month-to-month) variability increased
when shortening the administration interval from 4 to
2 weeks, and this change was predicted by the increased
reticulocyte long-term (month-to-month) variability (pri-
mary outcome).
These results however, should be looked at carefully,
taking into account the limitations of the study and the
possible sources of bias.
First, in absence of previous literature studies quantify-
ing the impact of different ESAs treatment and adminis-
tration protocols on hemoglobin temporal instability in
terms of both variability and temporal dependency over
time, we were not able to assume a degree of effective-
ness of therapy allowing us to estimate the sample size.
We therefore proposed the protocol to all patients under
hemodialysis at our centre at study begin.
Second, this is a randomized controlled study realized
in a “real life” scenario. In order to assess the pharma-
codynamic effect of ESAs on hemoglobin variability, an
“on-treatment” analysis was performed, restricting the
comparison of the treatments to the ideal patients-weeks,
that is, those without intercurrent potentially perturbing
event (hospitalization, transfusions, bleeding).
Ideally, the four administration protocols should have
been studied in a stable population, without intercurrent
illness, but this is far away of being the reality of a
hemodialysis station. A further characteristic of the dia-
lysis population is its high instability (deaths, trans-
plants, dialysis centre change), that explains the high
drop-out rate (only 50% of the patients included
reached the study end).
Conclusion
In conclusion, reticulocytes seemed to be a more sensi-
tive marker of time instability of the erythropoietic dy-
namic under ESAs therapy, their variability influencing
the hemoglobin response. As expected, shortening the ad-
ministration interval lessened the amplitude of reticulo-
cyte count fluctuations. However, surprisingly enough,
the same strategy was associated with an increased
month-to-month reticulocyte and hemoglobin instabil-
ity. This meaning, that in the clinical setting the favor-
able and unfavorable consequences of lengthening the
administration interval on hemoglobin variability tend
to counterbalance each other, contrarily to the results
of our previous published pharmacokinetic computer-
based simulation. However, even if these results arecomforting, the non-physiologic and extreme reticulocyte
count fluctuation over time using the monthly administra-
tion interval imposes prudence and suggests further
exploring the possible unfavorable consequences on
hemoglobin stability. Furthermore, the more protracted
reticulocyte response induced by C.E.R.A. (and even if the
differences comparing to Darbepoetin alfa were less than
expected) could explain both, the observed higher risk of
hemoglobin overshoot and the significant increase in effi-
cacy when shortening from once to twice a month its ad-
ministration interval.
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